RC48 with Avastin or Pyrotinib for HER2+ breast cancer after T-DXd
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have HER2-positive breast cancer (a specific type of cancer with high HER2 protein) that has spread or cannot be removed by surgery.
- You have already been treated with the drug T-DXd and your cancer got worse during or after that treatment.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are well enough to be up and about (ECOG score 0 or 1), meaning you can do most daily activities without help.
- Your liver, kidney, and blood cell counts are within acceptable ranges (checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
This trial tests a combination of two targeted drugs (Disitamab Vedotin and Pyrotinib) for people with HER2-positive early breast cancer. It aims to see if this treatment can improve outcomes before standard therapy.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
This trial tests whether combining the drug RC48 with chemotherapy can help people whose HER2-positive advanced breast cancer has stopped responding to a prior type of antibody-drug conjugate (ADC) therapy. It may offer a new treatment option for those whose cancer has progressed after previous treatments.
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.